Christine M Groth1, Nicole M Acquisto2, Tina Khadem3. 1. University of Rochester Medical Center-coordinating site., 601 Elmwood Ave. Box 638, Rochester, NY 14642, United States. Electronic address: christine_groth@urmc.rochester.edu. 2. University of Rochester Medical Center-coordinating site., 601 Elmwood Ave. Box 638, Rochester, NY 14642, United States. Electronic address: nicole_acquisto@urmc.rochester.edu. 3. University of Rochester Medical Center-coordinating site., 601 Elmwood Ave. Box 638, Rochester, NY 14642, United States. Electronic address: khademt@upmc.edu.
Abstract
PURPOSE: Characterize medication practices during and immediately after rapid sequence intubation (RSI) by provider/location and evaluate adverse drug events. MATERIALS AND METHODS: This was a multicenter, observational, cross-sectional study of adult and pediatric intensive care unit and emergency department patients over a 24-h period surrounding first intubation. RESULTS: A total of 404 patients from 34 geographically diverse institutions were included (mean age 58 ± 22 years, males 59%, pediatric 8%). During RSI, 21%, 87%, and 77% received pre-induction, induction, and paralysis, respectively. Significant differences in medication use by provider type were seen. Etomidate was administered to 58% with sepsis, but was not associated with adrenal insufficiency. Ketamine was associated with hypotension post-RSI [RR = 1.78 (1.36-2.35)] and use was low with traumatic brain injury/stroke (1.5%). Succinylcholine was given to 67% of patients with baseline bradycardia and was significantly associated with bradycardia post-RSI [RR = 1.81 (1.11-2.94)]. An additional 13% given succinylcholine had contraindications. Sedation practices post-RSI were not consistent with current practice guidelines and most receiving a non-depolarizing paralytic did not receive adequate sedation post-RSI. CONCLUSIONS: Medication practices during RSI vary amongst provider and medications are often used inappropriately. There is opportunity for optimization of medication use during RSI.
PURPOSE: Characterize medication practices during and immediately after rapid sequence intubation (RSI) by provider/location and evaluate adverse drug events. MATERIALS AND METHODS: This was a multicenter, observational, cross-sectional study of adult and pediatric intensive care unit and emergency department patients over a 24-h period surrounding first intubation. RESULTS: A total of 404 patients from 34 geographically diverse institutions were included (mean age 58 ± 22 years, males 59%, pediatric 8%). During RSI, 21%, 87%, and 77% received pre-induction, induction, and paralysis, respectively. Significant differences in medication use by provider type were seen. Etomidate was administered to 58% with sepsis, but was not associated with adrenal insufficiency. Ketamine was associated with hypotension post-RSI [RR = 1.78 (1.36-2.35)] and use was low with traumatic brain injury/stroke (1.5%). Succinylcholine was given to 67% of patients with baseline bradycardia and was significantly associated with bradycardia post-RSI [RR = 1.81 (1.11-2.94)]. An additional 13% given succinylcholine had contraindications. Sedation practices post-RSI were not consistent with current practice guidelines and most receiving a non-depolarizing paralytic did not receive adequate sedation post-RSI. CONCLUSIONS: Medication practices during RSI vary amongst provider and medications are often used inappropriately. There is opportunity for optimization of medication use during RSI.
Authors: Gerald Matchett; Irina Gasanova; Christina A Riccio; Dawood Nasir; Mary C Sunna; Brian J Bravenec; Omaira Azizad; Brian Farrell; Abu Minhajuddin; Jesse W Stewart; Lawrence W Liang; Tiffany Sun Moon; Pamela E Fox; Callie G Ebeling; Miakka N Smith; Devin Trousdale; Babatunde O Ogunnaike Journal: Intensive Care Med Date: 2021-12-14 Impact factor: 41.787
Authors: Nicholas M Mohr; Stephen G Pape; Dan Runde; Amy H Kaji; Ron M Walls; Calvin A Brown Journal: Acad Emerg Med Date: 2020-07-20 Impact factor: 3.451
Authors: Ryan D Pappal; Brian W Roberts; Winston Winkler; Lauren H Yaegar; Robert J Stephens; Brian M Fuller Journal: Crit Care Med Date: 2021-03-01 Impact factor: 9.296